Comparison of healthcare costs and resource utilization for overactive bladder patients in the United States persisting with mirabegron treatment or switching to onabotulinumtoxin A

Ng D B1, Espinosa R2, Johnson S2, Walker D1, Gooch K1

Research Type

Clinical

Abstract Category

Overactive Bladder

Abstract 481
Female Lower Urinary Tract Symptoms 1
Scientific Podium Short Oral Session 24
Thursday 14th September 2017
17:22 - 17:30
Cavaniglia A
Overactive Bladder Retrospective Study Detrusor Overactivity
1. Astellas Pharma Global Development, 2. Medicus Economics LLC
Presenter
D

Daniel Bin Ng

Links

Abstract